Anti-neutrophil-elastase defenses of the lower respiratory tract in α1-antitrypsin deficiency directly augmented with an aerosol of α1-antitrypsin

R. C. Hubbard, M. L. Brantly, S. E. Sellers, M. E. Mitchell, Ronald Crystal

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

Study Objective: To determine if aerosolization of purified human plasma α1-antitrypsin is an effective means for increasing lower respiratory anti-neutrophil-elastase defenses in α1-antitrypsin deficiency. Design: Nonrandomized, before-and-after trial with a 7-day treatment period. Companion studies in animals to determine lung epithelial permeability to α1-antitrypsin. Patients: Twelve patients with homozygous Z-type α1-antitrypsin deficiency and mild to moderate emphysema. Interventions: Aerosol administration of human plasma α1-antitrypsin, 100 mg every 12 hours for 7 days. Single, 100-mg aerosol dose to anesthetized shheep with indwelling thoracic lymph duct catheters for direct assessment of lung permeability. Measurements and Main Results: Treatment resulted in increased α1-antitrypsin levels in the lung epithelial lining fluid (0.28 ± 0.07 μM before therapy to 5.86 ± 1.03 μM after therapy) and increased anti-neutrophil-elastase capacity (0.78 ± 0.38 μM before therapy to 4.16 ± 0.95 μM after therapy). Aerosolized α1-antitrypsin diffused across the respiratory epithelium and entered lung interstitial lymph (in sheep) and reached the systemic circulation (in sheep and humans). No side effects were noted. Conclusion: Short-term aerosol administration of human plasma α1-antitrypsin to patients with α1-antitrypsin deficiency is safe and feasible, resulting in a return to normal of anti-neutrophil-elastase defenses in the lower respiratory tract. The aerosol approach, therefore, merits serious longterm evaluation as an alternative to other parenteral forms of administering therapeutic proteins.

Original languageEnglish
Pages (from-to)206-212
Number of pages7
JournalAnnals of Internal Medicine
Volume111
Issue number3
Publication statusPublished - 1 Jan 1989
Externally publishedYes

Fingerprint

Leukocyte Elastase
Aerosols
Respiratory System
Lung
Lymph
Therapeutics
Permeability
Sheep
Thoracic Duct
Respiratory Mucosa
Emphysema
Catheters

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Anti-neutrophil-elastase defenses of the lower respiratory tract in α1-antitrypsin deficiency directly augmented with an aerosol of α1-antitrypsin. / Hubbard, R. C.; Brantly, M. L.; Sellers, S. E.; Mitchell, M. E.; Crystal, Ronald.

In: Annals of Internal Medicine, Vol. 111, No. 3, 01.01.1989, p. 206-212.

Research output: Contribution to journalArticle

@article{2eb9112108e94ac492b3ddfd77436e62,
title = "Anti-neutrophil-elastase defenses of the lower respiratory tract in α1-antitrypsin deficiency directly augmented with an aerosol of α1-antitrypsin",
abstract = "Study Objective: To determine if aerosolization of purified human plasma α1-antitrypsin is an effective means for increasing lower respiratory anti-neutrophil-elastase defenses in α1-antitrypsin deficiency. Design: Nonrandomized, before-and-after trial with a 7-day treatment period. Companion studies in animals to determine lung epithelial permeability to α1-antitrypsin. Patients: Twelve patients with homozygous Z-type α1-antitrypsin deficiency and mild to moderate emphysema. Interventions: Aerosol administration of human plasma α1-antitrypsin, 100 mg every 12 hours for 7 days. Single, 100-mg aerosol dose to anesthetized shheep with indwelling thoracic lymph duct catheters for direct assessment of lung permeability. Measurements and Main Results: Treatment resulted in increased α1-antitrypsin levels in the lung epithelial lining fluid (0.28 ± 0.07 μM before therapy to 5.86 ± 1.03 μM after therapy) and increased anti-neutrophil-elastase capacity (0.78 ± 0.38 μM before therapy to 4.16 ± 0.95 μM after therapy). Aerosolized α1-antitrypsin diffused across the respiratory epithelium and entered lung interstitial lymph (in sheep) and reached the systemic circulation (in sheep and humans). No side effects were noted. Conclusion: Short-term aerosol administration of human plasma α1-antitrypsin to patients with α1-antitrypsin deficiency is safe and feasible, resulting in a return to normal of anti-neutrophil-elastase defenses in the lower respiratory tract. The aerosol approach, therefore, merits serious longterm evaluation as an alternative to other parenteral forms of administering therapeutic proteins.",
author = "Hubbard, {R. C.} and Brantly, {M. L.} and Sellers, {S. E.} and Mitchell, {M. E.} and Ronald Crystal",
year = "1989",
month = "1",
day = "1",
language = "English",
volume = "111",
pages = "206--212",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "3",

}

TY - JOUR

T1 - Anti-neutrophil-elastase defenses of the lower respiratory tract in α1-antitrypsin deficiency directly augmented with an aerosol of α1-antitrypsin

AU - Hubbard, R. C.

AU - Brantly, M. L.

AU - Sellers, S. E.

AU - Mitchell, M. E.

AU - Crystal, Ronald

PY - 1989/1/1

Y1 - 1989/1/1

N2 - Study Objective: To determine if aerosolization of purified human plasma α1-antitrypsin is an effective means for increasing lower respiratory anti-neutrophil-elastase defenses in α1-antitrypsin deficiency. Design: Nonrandomized, before-and-after trial with a 7-day treatment period. Companion studies in animals to determine lung epithelial permeability to α1-antitrypsin. Patients: Twelve patients with homozygous Z-type α1-antitrypsin deficiency and mild to moderate emphysema. Interventions: Aerosol administration of human plasma α1-antitrypsin, 100 mg every 12 hours for 7 days. Single, 100-mg aerosol dose to anesthetized shheep with indwelling thoracic lymph duct catheters for direct assessment of lung permeability. Measurements and Main Results: Treatment resulted in increased α1-antitrypsin levels in the lung epithelial lining fluid (0.28 ± 0.07 μM before therapy to 5.86 ± 1.03 μM after therapy) and increased anti-neutrophil-elastase capacity (0.78 ± 0.38 μM before therapy to 4.16 ± 0.95 μM after therapy). Aerosolized α1-antitrypsin diffused across the respiratory epithelium and entered lung interstitial lymph (in sheep) and reached the systemic circulation (in sheep and humans). No side effects were noted. Conclusion: Short-term aerosol administration of human plasma α1-antitrypsin to patients with α1-antitrypsin deficiency is safe and feasible, resulting in a return to normal of anti-neutrophil-elastase defenses in the lower respiratory tract. The aerosol approach, therefore, merits serious longterm evaluation as an alternative to other parenteral forms of administering therapeutic proteins.

AB - Study Objective: To determine if aerosolization of purified human plasma α1-antitrypsin is an effective means for increasing lower respiratory anti-neutrophil-elastase defenses in α1-antitrypsin deficiency. Design: Nonrandomized, before-and-after trial with a 7-day treatment period. Companion studies in animals to determine lung epithelial permeability to α1-antitrypsin. Patients: Twelve patients with homozygous Z-type α1-antitrypsin deficiency and mild to moderate emphysema. Interventions: Aerosol administration of human plasma α1-antitrypsin, 100 mg every 12 hours for 7 days. Single, 100-mg aerosol dose to anesthetized shheep with indwelling thoracic lymph duct catheters for direct assessment of lung permeability. Measurements and Main Results: Treatment resulted in increased α1-antitrypsin levels in the lung epithelial lining fluid (0.28 ± 0.07 μM before therapy to 5.86 ± 1.03 μM after therapy) and increased anti-neutrophil-elastase capacity (0.78 ± 0.38 μM before therapy to 4.16 ± 0.95 μM after therapy). Aerosolized α1-antitrypsin diffused across the respiratory epithelium and entered lung interstitial lymph (in sheep) and reached the systemic circulation (in sheep and humans). No side effects were noted. Conclusion: Short-term aerosol administration of human plasma α1-antitrypsin to patients with α1-antitrypsin deficiency is safe and feasible, resulting in a return to normal of anti-neutrophil-elastase defenses in the lower respiratory tract. The aerosol approach, therefore, merits serious longterm evaluation as an alternative to other parenteral forms of administering therapeutic proteins.

UR - http://www.scopus.com/inward/record.url?scp=0024403417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024403417&partnerID=8YFLogxK

M3 - Article

C2 - 2787611

AN - SCOPUS:0024403417

VL - 111

SP - 206

EP - 212

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 3

ER -